Inhibitory Effect of Bisdemethoxycurcumin on DNCB-Induced Atopic Dermatitis in Mice

• Published in: Molecules (Basel, Switzerland) Switzerland), 2022-12, Vol.28 (1), p.293
• Main Authors: Wang, Yanjie, Zhang, Ping, Zhang, Jingyu, Hong, Tie
• Format: Article
• Language: English
• Subjects: Analysis; Animals; Aquatic plants; Atopic dermatitis; bisdemethoxycurcumin; Care and treatment; Chemokines; Chemokines - genetics; Chemokines - metabolism; Cytokines; Cytokines - metabolism; Cytotoxicity; Dermatitis; Dermatitis, Atopic - chemically induced; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - pathology; Diagnosis; Dichlorobenzene; Dinitrochlorobenzene - metabolism; Eczema; Edema; Erythema; Food allergies; Gene expression; HaCaT cells; Hay fever; Health aspects; Herbal medicine; Immune response; In vivo methods and tests; Inflammation; Inflammatory response; Keratinocytes; MAP kinase; MAPK; Medicine, Botanic; Medicine, Herbal; Mice; Mice, Inbred BALB C; NF-kappa B - metabolism; NF-κB; NF-κB protein; Pathogenesis; Phosphorylation; Proteins; Rhinitis; Rhizomes; RNA, Messenger - metabolism; Signal transduction; Signs and symptoms; Skin; Skin diseases; Skin lesions; Spleen; Thickness; Tumor Necrosis Factor-alpha - metabolism; Tumor necrosis factor-TNF; Tumor necrosis factor-α; γ-Interferon
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules28010293

Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Bisdemethoxycurcumin (BDMC) is an ingredient from the rhizome of the traditional Chinese herbal medicine turmeric. BDMC has been reported to have important pharmacological properties, such as anti-inflammatory, antioxidant, antitumor and antiproliferative activities. However, its effect on atopic dermatitis has not been reported. The purpose of our study was to demonstrate the effectiveness of BDMC on TNF-α/IFNγ-stimulated HaCaT cells and on 2,4-dinitrochlorobenzene (DNCB)-induced AD mice. Our studies showed in vitro that BDMC was able to significantly inhibit the mRNA expression of chemokines and cytokines in TNF-α/IFN-γ-stimulated HaCaT cells and alleviate their inflammatory response. Our studies found in vivo that BDMC was able to significantly improve the symptoms of DNCB-induced AD skin lesions, decrease the number of scratches, ear thickness, and spleen index, improve inflammatory cells and mast cell infiltration and decrease skin thickness. Moreover, it was also able to inhibit the mRNA expression levels of chemokines and inflammatory cytokines and the activation of the MAPK and NF-κB signaling pathways. Thus, the results indicated that BDMC can improve atopic dermatitis in mice and that further clinical studies are warranted on its treatment of AD.